Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025

Stock Track

2024-12-10

BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.

Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:

The Chinese government's supportive policy on innovative drugs and pricing
An expected improvement in biotech funding environment

According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1183254431"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183254431\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1183254431?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183254431","market":"us","top_or_hot":-1,"title":"Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025","media":"Stock Track","content":"<p>BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.</p>\n\n<p>Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:</p>\n\n<ul>\n<li>The Chinese government's supportive policy on innovative drugs and pricing</li>\n<li>An expected improvement in biotech funding environment</li>\n</ul>\n\n<p>According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-12-10 22:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.</p>\n\n<p>Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:</p>\n\n<ul>\n<li>The Chinese government's supportive policy on innovative drugs and pricing</li>\n<li>An expected improvement in biotech funding environment</li>\n</ul>\n\n<p>According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1183254431","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183254431","pubTimestamp":1733841298,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeiGene, a Chinese biopharmaceutical company, saw its stock  plummet by 5.83% on Tuesday during the intraday trading session.Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:. The Chinese government's supportive policy on innovative drugs and pricing. According to Cyrus Ng, an analyst at Deuts","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"股票赛道百济神州股价周二暴跌5.83%预计2025年复苏","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1},"content_text":"BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.\nDespite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:\n\nThe Chinese government's supportive policy on innovative drugs and pricing\nAn expected improvement in biotech funding environment\n\nAccording to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}